ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 64 filers reported holding ALPINE IMMUNE SCIENCES INC in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $218,088 | -53.7% | 19,047 | -58.5% | 0.00% | – |
| Q2 2023 | $471,338 | +663.8% | 45,850 | +473.6% | 0.00% | – |
| Q1 2023 | $61,706 | +268.9% | 7,993 | +251.2% | 0.00% | – |
| Q4 2022 | $16,729 | +67.3% | 2,276 | +89.7% | 0.00% | – |
| Q2 2022 | $10,000 | -54.5% | 1,200 | -49.3% | 0.00% | – |
| Q1 2022 | $22,000 | -68.6% | 2,369 | -52.6% | 0.00% | – |
| Q4 2021 | $70,000 | +483.3% | 4,996 | +337.5% | 0.00% | – |
| Q3 2021 | $12,000 | +71.4% | 1,142 | +65.7% | 0.00% | – |
| Q1 2021 | $7,000 | -41.7% | 689 | -50.9% | 0.00% | – |
| Q3 2020 | $12,000 | +9.1% | 1,404 | +25.8% | 0.00% | – |
| Q2 2020 | $11,000 | +120.0% | 1,116 | -1.2% | 0.00% | – |
| Q2 2019 | $5,000 | +150.0% | 1,129 | +329.3% | 0.00% | – |
| Q1 2019 | $2,000 | -66.7% | 263 | -84.3% | 0.00% | – |
| Q4 2018 | $6,000 | -62.5% | 1,676 | -21.6% | 0.00% | – |
| Q2 2018 | $16,000 | +100.0% | 2,137 | +107.5% | 0.00% | – |
| Q1 2018 | $8,000 | – | 1,030 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |